potassium two pore domain channel subfamily K member 6
RGD ID:
621450
Description:
Enables potassium channel activity. Predicted to be involved in potassium ion transmembrane transport and stabilization of membrane potential. Predicted to act upstream of or within negative regulation of systemic arterial blood pressure and regulation of resting membrane potential. Predicted to be located in membrane. Biomarker of brain infarction. Orthologous to human KCNK6 (potassium two pore domain channel subfamily K member 6); INTERACTS WITH 1,3-dinitrobenzene; 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine.
LOC100909725; potassium channel subfamily K member 6; potassium channel subfamily K member 6 (TWIK-2); potassium channel subfamily K member 6-like; potassium channel, subfamily K, member 6; potassium channel, subfamily K, member 6 (TWIK-2); potassium channel, two pore domain subfamily K, member 6; potassium inwardly-rectifying channel, subfamily K, member 6; Twik-2; Twik2
[Estradiol binds to ESR2 protein] which results in increased expression of KCNK6 mRNA and [Estradiol co-treated with TGFB1 protein] results in increased expression of KCNK6 mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNK6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK6 mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNK6 mRNA
[Plasticizers co-treated with Cosmetics co-treated with Flame Retardants co-treated with perfluorooctanoic acid co-treated with Phytoestrogens] results in decreased expression of KCNK6 mRNA
[Plasticizers co-treated with Cosmetics co-treated with Flame Retardants co-treated with perfluorooctanoic acid co-treated with Phytoestrogens] results in decreased expression of KCNK6 mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNK6 mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNK6 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK6 mRNA